1 00:00:00,160 --> 00:00:02,799 Hello, everyone. This is Erica Spicer Mason with 2 00:00:02,799 --> 00:00:05,120 Becker's Healthcare. Thank you so much for tuning 3 00:00:05,120 --> 00:00:07,859 into the Becker's Healthcare podcast series today. 4 00:00:08,480 --> 00:00:10,240 So today, we're going to talk about how 5 00:00:10,240 --> 00:00:13,599 health systems are reshaping clinical decision making by 6 00:00:13,599 --> 00:00:16,504 turning molecular data into actionable care. 7 00:00:16,804 --> 00:00:19,464 And joining me for this conversation is Solomon 8 00:00:19,524 --> 00:00:20,024 Moskovich, 9 00:00:20,484 --> 00:00:22,344 the president of clinical diagnostics 10 00:00:22,644 --> 00:00:23,384 at Natera. 11 00:00:24,004 --> 00:00:26,085 Solomon, welcome to the podcast. It's so great 12 00:00:26,085 --> 00:00:27,304 to have you with us today. 13 00:00:27,820 --> 00:00:29,660 Thank you. It's great to be here. Well, 14 00:00:29,660 --> 00:00:31,739 I'm excited to learn more about what's going 15 00:00:31,739 --> 00:00:33,899 on at Natera. And before we get into 16 00:00:33,899 --> 00:00:36,219 that conversation, I wanted to just learn a 17 00:00:36,219 --> 00:00:37,979 little bit more about you and your work 18 00:00:37,979 --> 00:00:38,960 in health care. 19 00:00:39,340 --> 00:00:41,020 Really feel free to share whatever you think 20 00:00:41,020 --> 00:00:43,119 will be helpful for our listeners to know. 21 00:00:44,034 --> 00:00:46,614 Wonderful. Yeah. First, I wanna introduce the company, 22 00:00:47,155 --> 00:00:49,254 and I can talk about myself briefly. 23 00:00:50,034 --> 00:00:52,214 Natera has been around for about twenty years, 24 00:00:52,994 --> 00:00:53,894 started by 25 00:00:54,274 --> 00:00:56,695 engineers out of Stanford University 26 00:00:57,634 --> 00:00:58,375 and MIT, 27 00:00:59,370 --> 00:01:02,270 and the company has developed unique and patented 28 00:01:02,329 --> 00:01:03,870 technology for analyzing 29 00:01:04,730 --> 00:01:05,230 DNA 30 00:01:05,849 --> 00:01:06,670 from blood. 31 00:01:07,130 --> 00:01:09,709 And, we've had an incredible impact 32 00:01:10,329 --> 00:01:13,049 now applying our technologies to improve care for 33 00:01:13,049 --> 00:01:15,295 pregnant women, for people with cancer, 34 00:01:15,754 --> 00:01:17,375 and for people with organ transplants 35 00:01:17,915 --> 00:01:19,375 and chronic kidney disease. 36 00:01:20,395 --> 00:01:23,275 We, have a a very significant pipeline to 37 00:01:23,275 --> 00:01:25,454 expand the applications for our technologies, 38 00:01:26,489 --> 00:01:29,689 And, I'm very proud that we're serving millions 39 00:01:29,689 --> 00:01:31,230 of patients every year, 40 00:01:31,769 --> 00:01:34,250 and and their physicians. These are medical tests 41 00:01:34,250 --> 00:01:35,709 ordered by by physicians. 42 00:01:36,489 --> 00:01:36,989 Myself, 43 00:01:37,290 --> 00:01:39,209 I've been at the company for almost fifteen 44 00:01:39,209 --> 00:01:39,709 years, 45 00:01:40,010 --> 00:01:41,310 got a background in mathematics, 46 00:01:42,375 --> 00:01:42,814 and, 47 00:01:43,255 --> 00:01:46,694 I'm very passionate about the impact that our 48 00:01:46,694 --> 00:01:49,015 technologies have on patients, including many in my 49 00:01:49,015 --> 00:01:51,015 own family. So I'm really glad to be 50 00:01:51,015 --> 00:01:51,515 here. 51 00:01:52,454 --> 00:01:54,314 It's great to have you with us, Solomon, 52 00:01:54,375 --> 00:01:55,995 and I appreciate the overview 53 00:01:56,420 --> 00:01:58,500 about Natera and learning a little bit more 54 00:01:58,500 --> 00:02:00,659 about you as well. And it sounds like 55 00:02:00,659 --> 00:02:02,359 the company really is overseeing, 56 00:02:03,780 --> 00:02:06,439 this technology that's helping a number of conditions 57 00:02:06,500 --> 00:02:08,199 and and really important 58 00:02:08,895 --> 00:02:11,375 conditions for hospitals and health systems when we're 59 00:02:11,375 --> 00:02:14,175 talking about, of course, pregnancy, cancer, chronic kidney 60 00:02:14,175 --> 00:02:14,675 disease. 61 00:02:15,134 --> 00:02:17,055 So excited to get some of your insights 62 00:02:17,055 --> 00:02:19,055 on that. But I wanted to start a 63 00:02:19,055 --> 00:02:20,834 little bit high level and acknowledge 64 00:02:21,330 --> 00:02:23,990 that precision medicine, it it's evolved rapidly 65 00:02:24,290 --> 00:02:25,969 in the last decade. I I feel like 66 00:02:25,969 --> 00:02:29,250 every year we hear more about really impressive 67 00:02:29,250 --> 00:02:32,230 advancements in this field. So from your perspective, 68 00:02:32,530 --> 00:02:34,935 what are the most important advancements in in 69 00:02:34,935 --> 00:02:37,514 how we identify disease status and guide care? 70 00:02:38,534 --> 00:02:41,435 Yeah. This field has, has evolved so quickly. 71 00:02:41,974 --> 00:02:44,375 It's a very, very exciting time to be 72 00:02:44,375 --> 00:02:44,875 in 73 00:02:45,254 --> 00:02:46,955 genetics and genetic medicine, 74 00:02:47,814 --> 00:02:48,474 and precision 75 00:02:48,854 --> 00:02:50,074 medicine. So, 76 00:02:50,430 --> 00:02:51,169 you know, the 77 00:02:51,709 --> 00:02:53,789 the prior ten years, I think, were full 78 00:02:53,789 --> 00:02:55,009 of discoveries, 79 00:02:56,349 --> 00:02:58,289 about what you could do with information, 80 00:02:59,069 --> 00:03:01,889 genomic profiling information from a 81 00:03:02,269 --> 00:03:04,689 tumor sample from a patient with cancer. 82 00:03:05,245 --> 00:03:07,885 And that led to really growth of the 83 00:03:07,885 --> 00:03:09,665 whole concept of precision oncology. 84 00:03:10,365 --> 00:03:12,685 If you find a certain mutation in a 85 00:03:12,685 --> 00:03:14,944 gene in the patient's cancer, that might 86 00:03:15,325 --> 00:03:17,724 that might, mean that the patient is likely 87 00:03:17,724 --> 00:03:19,585 to benefit from a targeted therapy, 88 00:03:20,060 --> 00:03:22,560 for example, and there's just been an explosion 89 00:03:22,620 --> 00:03:25,519 of different gene linked therapies, 90 00:03:26,620 --> 00:03:29,340 from multiple different biopharma companies, which have made 91 00:03:29,340 --> 00:03:31,519 a huge impact on on patient survival. 92 00:03:32,534 --> 00:03:35,275 There's also been the introduction of immunotherapies 93 00:03:35,814 --> 00:03:37,034 and immuno oncology, 94 00:03:37,574 --> 00:03:39,414 unleashing the power of the patient of the 95 00:03:39,414 --> 00:03:40,954 patient's own immune system, 96 00:03:42,454 --> 00:03:43,674 to fight cancer. 97 00:03:44,490 --> 00:03:44,990 But, 98 00:03:45,849 --> 00:03:48,650 the predictive tools for who is going to 99 00:03:48,650 --> 00:03:50,750 benefit, who needs additional therapy, 100 00:03:51,129 --> 00:03:53,930 who maybe does not need additional therapy and 101 00:03:53,930 --> 00:03:56,189 can avoid the unnecessary toxicity, 102 00:03:57,290 --> 00:03:58,189 and cost 103 00:03:58,564 --> 00:04:00,905 of being on therapy, sometimes for years. 104 00:04:01,685 --> 00:04:03,865 That has, it has really, 105 00:04:04,564 --> 00:04:05,305 not been 106 00:04:05,925 --> 00:04:08,884 acted upon until recently. And so the the 107 00:04:08,884 --> 00:04:09,384 big 108 00:04:09,844 --> 00:04:13,305 new area of innovation in precision oncology, specifically, 109 00:04:14,459 --> 00:04:15,199 has been 110 00:04:15,500 --> 00:04:19,439 MRD testing. That's molecular residual disease testing. 111 00:04:20,139 --> 00:04:23,500 And, Natera is the, the leader in solid 112 00:04:23,500 --> 00:04:24,560 tumor MRD. 113 00:04:25,100 --> 00:04:27,199 I'll explain the what the product does, 114 00:04:27,855 --> 00:04:29,235 but its purpose 115 00:04:29,855 --> 00:04:31,555 is to identify disease 116 00:04:32,175 --> 00:04:33,634 circulating in the blood, 117 00:04:34,415 --> 00:04:36,894 and identifying, you know, which patients still have 118 00:04:36,894 --> 00:04:39,154 disease, residual disease, MRD, 119 00:04:39,550 --> 00:04:42,750 and need additional therapy, and which patients maybe 120 00:04:42,750 --> 00:04:45,470 do not have detectable disease in their blood 121 00:04:45,470 --> 00:04:47,090 after some curative intervention 122 00:04:47,629 --> 00:04:50,990 and can safely avoid unnecessary therapy going forward 123 00:04:50,990 --> 00:04:52,850 and and have amazing outcomes. 124 00:04:53,685 --> 00:04:56,904 So Natera developed a test called the Signatera 125 00:04:57,605 --> 00:05:00,345 test. It's the first ever in history 126 00:05:01,045 --> 00:05:03,145 personalized test for every single patient. 127 00:05:04,245 --> 00:05:05,925 So the way that test works is that 128 00:05:05,925 --> 00:05:06,085 we, 129 00:05:06,970 --> 00:05:08,970 we do a a whole exome or whole 130 00:05:08,970 --> 00:05:09,949 genome sequence 131 00:05:10,410 --> 00:05:13,050 of the tumor sample from resection or from 132 00:05:13,050 --> 00:05:13,550 biopsy. 133 00:05:14,009 --> 00:05:17,069 We identify the unique complement of mutations 134 00:05:17,930 --> 00:05:18,830 in that cancer 135 00:05:19,274 --> 00:05:21,115 that are not present in the background DNA, 136 00:05:21,115 --> 00:05:23,294 and then we custom design and manufacture 137 00:05:24,235 --> 00:05:27,035 a test for every single patient's cancer that 138 00:05:27,035 --> 00:05:28,894 only looks at that unique signature 139 00:05:29,435 --> 00:05:30,095 of mutations 140 00:05:30,475 --> 00:05:31,834 and looks for it in the blood, 141 00:05:32,639 --> 00:05:35,439 which is extremely highly specific. The test can 142 00:05:35,439 --> 00:05:36,419 detect recurrence, 143 00:05:36,959 --> 00:05:38,639 like, a year earlier than you'd see it 144 00:05:38,639 --> 00:05:39,379 on a scan, 145 00:05:40,240 --> 00:05:42,259 and with extremely high specificity. 146 00:05:43,199 --> 00:05:45,039 And what that's enabled and that and that 147 00:05:45,039 --> 00:05:48,019 works across cancer types. It's extraordinary. 148 00:05:49,095 --> 00:05:49,995 And that has enabled, 149 00:05:50,774 --> 00:05:53,355 really a, a sea change in how 150 00:05:53,894 --> 00:05:54,954 in how oncology 151 00:05:55,654 --> 00:05:56,634 is practiced 152 00:05:57,014 --> 00:05:59,514 across the country and increasingly across the world, 153 00:05:59,814 --> 00:06:00,954 with huge implications 154 00:06:02,889 --> 00:06:03,949 for health economics 155 00:06:04,410 --> 00:06:05,949 as well as clinical outcomes. 156 00:06:06,410 --> 00:06:08,170 So, you know, I'm I'm looking forward to 157 00:06:08,170 --> 00:06:09,870 getting to the discussion with you 158 00:06:10,250 --> 00:06:10,750 about 159 00:06:11,290 --> 00:06:13,790 how Natera is partnering with health systems 160 00:06:14,170 --> 00:06:15,550 and health system executives 161 00:06:16,154 --> 00:06:18,394 to make sure that these technologies are are 162 00:06:18,394 --> 00:06:20,495 deployed in an evidence based way 163 00:06:21,035 --> 00:06:23,754 that not only improves patient care and outcomes, 164 00:06:23,754 --> 00:06:26,254 but, also, it makes a really big difference 165 00:06:26,314 --> 00:06:29,035 for the ballooning health care costs in our 166 00:06:29,035 --> 00:06:29,535 country. 167 00:06:30,394 --> 00:06:30,894 And 168 00:06:31,349 --> 00:06:33,349 and, you know, that has an implication not 169 00:06:33,349 --> 00:06:35,669 only in cancer, but in the other disease 170 00:06:35,669 --> 00:06:37,370 areas where we're operating. 171 00:06:39,349 --> 00:06:41,189 Yeah. Solomon, thank you so much for the 172 00:06:41,189 --> 00:06:41,689 overview. 173 00:06:42,310 --> 00:06:45,209 It's really exciting to hear about these advancements 174 00:06:45,349 --> 00:06:48,175 and and what's possible now in precision medicine 175 00:06:48,175 --> 00:06:49,555 and testing and diagnostics. 176 00:06:50,654 --> 00:06:52,495 And as health systems, to your point, as 177 00:06:52,495 --> 00:06:52,995 they're 178 00:06:53,615 --> 00:06:56,654 looking more into how to integrate some of 179 00:06:56,654 --> 00:07:00,334 these innovations into routine care and routine decision 180 00:07:00,334 --> 00:07:00,834 making, 181 00:07:01,470 --> 00:07:03,870 What challenges are you seeing leaders face as 182 00:07:03,870 --> 00:07:06,830 they bring these more sophisticated tools into their 183 00:07:06,830 --> 00:07:07,810 clinical workflows? 184 00:07:08,750 --> 00:07:11,310 Yeah. There's some there's some significant challenges, but 185 00:07:11,310 --> 00:07:13,250 also with that comes huge opportunities. 186 00:07:15,334 --> 00:07:16,795 So the first step to 187 00:07:17,175 --> 00:07:17,675 integrating, 188 00:07:18,455 --> 00:07:19,355 new diagnostics 189 00:07:19,814 --> 00:07:22,875 and new precision medicine tools into care is 190 00:07:23,014 --> 00:07:23,514 generating 191 00:07:24,375 --> 00:07:25,514 the clinical evidence. 192 00:07:26,230 --> 00:07:28,629 And that's an area that that Natera and 193 00:07:28,629 --> 00:07:32,490 our partners have invested really significantly. We've got 194 00:07:32,550 --> 00:07:35,529 hundreds of peer reviewed papers and scientific 195 00:07:36,149 --> 00:07:37,370 presentations across 196 00:07:37,830 --> 00:07:39,509 not only cancer, but also, 197 00:07:40,675 --> 00:07:41,175 detecting 198 00:07:41,714 --> 00:07:44,535 genetic abnormalities during pregnancy and 199 00:07:44,995 --> 00:07:45,495 identifying, 200 00:07:46,435 --> 00:07:47,254 different predispositions, 201 00:07:48,435 --> 00:07:51,095 towards chronic kidney disease and and more. 202 00:07:51,634 --> 00:07:53,714 And so we've generated that evidence, and we're 203 00:07:53,714 --> 00:07:57,169 continuing to invest now over half $1,000,000,000. 204 00:07:57,389 --> 00:07:59,810 That's with a b. Over half $1,000,000,000 205 00:08:00,110 --> 00:08:02,509 this year and next year and and going 206 00:08:02,509 --> 00:08:04,209 forward to continue driving 207 00:08:04,669 --> 00:08:06,449 that innovation and that evidence. 208 00:08:06,750 --> 00:08:08,269 But that's just the first step. So how 209 00:08:08,269 --> 00:08:10,965 do you integrate it into care once you're 210 00:08:10,965 --> 00:08:13,785 convinced you want it? And that's where Natera 211 00:08:14,085 --> 00:08:16,025 is partnering with health systems 212 00:08:16,564 --> 00:08:17,465 to deploy 213 00:08:18,004 --> 00:08:20,105 artificial intelligence based solutions 214 00:08:20,405 --> 00:08:22,985 to help identify the patients who are eligible 215 00:08:23,720 --> 00:08:24,620 for an intervention, 216 00:08:25,000 --> 00:08:26,300 eligible for a test, 217 00:08:26,840 --> 00:08:30,540 and really develop the clinical decision support 218 00:08:31,400 --> 00:08:32,700 tools and solutions 219 00:08:33,160 --> 00:08:34,299 that are going to 220 00:08:34,759 --> 00:08:37,340 improve adoption of evidence based medicine, 221 00:08:37,799 --> 00:08:39,420 identify gaps in care, 222 00:08:40,004 --> 00:08:42,585 integrate seamlessly with the electronic medical records. 223 00:08:43,285 --> 00:08:46,024 Ornateira is already integrated as a clinical, 224 00:08:47,045 --> 00:08:50,165 laboratory across, really, most of the systems across 225 00:08:50,165 --> 00:08:53,205 the country now and measure those outcomes and 226 00:08:53,205 --> 00:08:56,459 and measure the any gaps and and potentially, 227 00:08:56,759 --> 00:08:59,000 you know, improvements in care from deploying these 228 00:08:59,000 --> 00:09:01,980 solutions. So we're super excited about, 229 00:09:02,519 --> 00:09:05,399 how AI enables us and our partners to 230 00:09:05,399 --> 00:09:06,699 accelerate that effort, 231 00:09:07,079 --> 00:09:09,259 and ultimately improve patient care. 232 00:09:10,784 --> 00:09:13,584 Yeah. And I appreciate you touching on the 233 00:09:13,584 --> 00:09:15,924 role AI is playing here, Solomon, 234 00:09:16,304 --> 00:09:18,225 because I I know that digital tools and 235 00:09:18,225 --> 00:09:20,884 AI are becoming more essential to helping clinicians 236 00:09:21,264 --> 00:09:22,245 also translate 237 00:09:22,625 --> 00:09:23,125 complex 238 00:09:23,490 --> 00:09:24,389 molecular data 239 00:09:24,850 --> 00:09:27,570 into those clear care pathways and next steps 240 00:09:27,570 --> 00:09:28,470 as you've mentioned. 241 00:09:29,009 --> 00:09:30,929 So where are you seeing these technologies make 242 00:09:30,929 --> 00:09:33,429 the biggest difference right now, and what opportunities 243 00:09:33,649 --> 00:09:35,970 do you think they present for the future 244 00:09:35,970 --> 00:09:37,190 of precision medicine? 245 00:09:38,465 --> 00:09:40,785 Yeah. I'll give two examples, two or three 246 00:09:40,785 --> 00:09:42,544 examples that I think can really paint the 247 00:09:42,544 --> 00:09:44,565 picture of where things are going. 248 00:09:45,264 --> 00:09:46,965 So the first is in, 249 00:09:47,745 --> 00:09:49,044 is in cancer management. 250 00:09:49,424 --> 00:09:51,105 So we just had a New England Journal 251 00:09:51,105 --> 00:09:51,764 of Medicine, 252 00:09:52,570 --> 00:09:53,070 publication 253 00:09:53,450 --> 00:09:55,950 concurrent with a major presentation at the European 254 00:09:56,009 --> 00:09:57,389 Society of Medical Oncology 255 00:09:58,250 --> 00:09:59,230 showing that 256 00:09:59,850 --> 00:10:00,350 MRD 257 00:10:00,730 --> 00:10:01,230 guided 258 00:10:01,850 --> 00:10:05,644 care that's using Signatera, our MRD test. The 259 00:10:05,644 --> 00:10:08,764 Signatera MRD guided care in the adjuvant setting 260 00:10:08,764 --> 00:10:11,105 for muscle invasive bladder cancer patients, 261 00:10:12,524 --> 00:10:13,424 can improve 262 00:10:14,205 --> 00:10:16,865 overall survival by over forty percent, 263 00:10:17,804 --> 00:10:20,544 by treating MRD positive patients 264 00:10:22,160 --> 00:10:22,980 with immunotherapy 265 00:10:24,080 --> 00:10:25,059 and completely 266 00:10:25,440 --> 00:10:27,460 avoiding any adjuvant treatment 267 00:10:28,000 --> 00:10:31,200 for muscle invasive bladder cancer patients who are 268 00:10:31,200 --> 00:10:33,620 Signatera negative and who stay negative, 269 00:10:34,654 --> 00:10:37,294 after surgery. So that's more than half of 270 00:10:37,294 --> 00:10:37,794 patients 271 00:10:38,495 --> 00:10:41,294 are negative for their for residual disease after 272 00:10:41,294 --> 00:10:43,314 surgery and can safely avoid 273 00:10:43,694 --> 00:10:44,194 treatment, 274 00:10:44,975 --> 00:10:47,054 which is just incredible because the the prior 275 00:10:47,054 --> 00:10:48,034 standard of care 276 00:10:48,414 --> 00:10:50,549 is to treat all of those patients with 277 00:10:50,549 --> 00:10:51,049 immunotherapy 278 00:10:51,830 --> 00:10:52,889 for over a year, 279 00:10:53,269 --> 00:10:56,470 which is expensive, which is toxic, and which 280 00:10:56,470 --> 00:10:58,169 we've proven is just unnecessary 281 00:10:58,789 --> 00:11:01,370 for most patients. So that's just one example. 282 00:11:02,389 --> 00:11:03,049 And then 283 00:11:03,815 --> 00:11:06,294 another example is in chronic kidney disease. So 284 00:11:06,294 --> 00:11:08,455 this is now outside of cancer. There's a 285 00:11:08,455 --> 00:11:10,075 different test. It's called the rinosyte 286 00:11:10,534 --> 00:11:11,034 test, 287 00:11:11,735 --> 00:11:14,634 and that is a test for germline mutations 288 00:11:15,414 --> 00:11:17,195 that are associated with, 289 00:11:17,710 --> 00:11:19,649 different types of chronic kidney disease. 290 00:11:20,110 --> 00:11:21,409 And there's just been 291 00:11:21,950 --> 00:11:22,690 a significant 292 00:11:23,149 --> 00:11:24,690 inflection point in, 293 00:11:25,549 --> 00:11:28,429 in CKD recently, which, by the way, affects 294 00:11:28,429 --> 00:11:31,404 over forty million Americans at the diagnosis of 295 00:11:31,404 --> 00:11:33,485 chronic kidney disease. And the goal is to 296 00:11:33,485 --> 00:11:33,985 avoid 297 00:11:34,365 --> 00:11:37,105 progressing to end stage renal disease and dialysis 298 00:11:38,044 --> 00:11:39,824 and needing an organ transplant. 299 00:11:40,284 --> 00:11:42,065 But in the past year and a half, 300 00:11:42,559 --> 00:11:43,620 the amount of evidence 301 00:11:44,000 --> 00:11:47,220 and new guideline recommendations for genetic testing 302 00:11:47,759 --> 00:11:49,379 of patients who have symptoms 303 00:11:50,000 --> 00:11:53,059 of kidney disease has increased significantly. 304 00:11:53,440 --> 00:11:54,855 So think of where, like, 305 00:11:55,254 --> 00:11:58,315 BRCA testing was twenty years ago for identifying 306 00:11:58,375 --> 00:12:00,235 patients who are predisposed towards 307 00:12:00,695 --> 00:12:02,475 breast cancer, ovarian cancer, 308 00:12:03,095 --> 00:12:05,595 and other, like, inherited types of cancers. 309 00:12:06,375 --> 00:12:09,355 Genetics in chronic kidney disease is where 310 00:12:09,730 --> 00:12:11,190 cancer was twenty years ago. 311 00:12:11,730 --> 00:12:13,649 And so there's gonna be a sea change 312 00:12:13,649 --> 00:12:14,149 in, 313 00:12:14,850 --> 00:12:16,549 how those patients are diagnosed, 314 00:12:17,570 --> 00:12:20,149 and how they're managed based on their genetic, 315 00:12:21,169 --> 00:12:22,389 their genetic status. 316 00:12:22,929 --> 00:12:23,429 So 317 00:12:23,934 --> 00:12:26,254 the challenge, though, for adoption in a system 318 00:12:26,254 --> 00:12:26,754 is, 319 00:12:27,055 --> 00:12:28,195 okay. I've got, 320 00:12:28,654 --> 00:12:31,215 some cases, over a million patients in my 321 00:12:31,215 --> 00:12:31,715 system 322 00:12:32,095 --> 00:12:34,815 who have various signs and symptoms of kidney 323 00:12:34,815 --> 00:12:35,315 disease, 324 00:12:35,855 --> 00:12:39,029 and their, you know, their records in the 325 00:12:39,029 --> 00:12:41,669 primary care setting might not even have a 326 00:12:41,669 --> 00:12:42,169 diagnosis 327 00:12:42,549 --> 00:12:45,509 of CKD, but they have symptoms. So how 328 00:12:45,509 --> 00:12:46,730 do you go and identify 329 00:12:47,589 --> 00:12:50,490 those patients who need to get a test 330 00:12:51,865 --> 00:12:54,184 and actually get them that care? How do 331 00:12:54,184 --> 00:12:56,664 you close that care gap? And that's where 332 00:12:56,664 --> 00:12:58,365 these, digitally enabled, 333 00:12:58,825 --> 00:13:00,204 and AI driven solutions 334 00:13:00,584 --> 00:13:02,345 start to play a big role. So we're 335 00:13:02,345 --> 00:13:04,745 excited to part we're partnering with several different 336 00:13:04,745 --> 00:13:05,245 systems 337 00:13:05,704 --> 00:13:06,445 right now, 338 00:13:07,000 --> 00:13:09,480 to identify those patients in a in an 339 00:13:09,480 --> 00:13:09,980 intelligent 340 00:13:10,600 --> 00:13:13,100 EMR integrated manner and to get them, 341 00:13:13,639 --> 00:13:15,500 tested and then get them the right intervention 342 00:13:15,559 --> 00:13:17,579 depending on the result of that test. 343 00:13:18,039 --> 00:13:19,879 So I think those are that's two examples. 344 00:13:19,879 --> 00:13:21,819 I'll just I'll just plug one other one, 345 00:13:21,965 --> 00:13:23,424 and that is early cancer 346 00:13:23,884 --> 00:13:26,325 screening. So this is now you know, there 347 00:13:26,445 --> 00:13:27,424 there's been, 348 00:13:28,205 --> 00:13:29,345 a really exciting, 349 00:13:31,004 --> 00:13:32,384 innovation in the field, 350 00:13:33,004 --> 00:13:35,105 doing blood based cancer testing 351 00:13:35,490 --> 00:13:39,089 to find colorectal cancer and, and soon other 352 00:13:39,089 --> 00:13:41,250 cancer types as well for patients who are 353 00:13:41,250 --> 00:13:42,309 otherwise asymptomatic. 354 00:13:43,490 --> 00:13:45,169 So how do you do that? Right? How 355 00:13:45,169 --> 00:13:47,669 do you deploy a population level 356 00:13:48,355 --> 00:13:49,174 test like that, 357 00:13:49,794 --> 00:13:52,035 with the expectation that it's going to detect 358 00:13:52,035 --> 00:13:54,054 cancer at an earlier stage, 359 00:13:54,914 --> 00:13:57,495 which everyone knows is linked with better outcomes? 360 00:13:57,554 --> 00:13:59,715 And, again, that's an area where the terrorists 361 00:13:59,715 --> 00:14:00,695 taking a leadership, 362 00:14:01,649 --> 00:14:02,149 approach, 363 00:14:02,529 --> 00:14:04,850 both with developing what we believe is gonna 364 00:14:04,850 --> 00:14:06,470 be, you know, a leading 365 00:14:07,169 --> 00:14:07,669 performance 366 00:14:08,529 --> 00:14:09,750 early cancer test, 367 00:14:10,769 --> 00:14:12,309 based on methylation technology 368 00:14:13,009 --> 00:14:16,075 as well as the smartest ways to partner 369 00:14:16,075 --> 00:14:18,254 with systems to actually deploy that technology 370 00:14:18,794 --> 00:14:21,134 to help their patients at a wide scale. 371 00:14:21,355 --> 00:14:23,754 Those are three good examples of, of how 372 00:14:23,754 --> 00:14:24,894 we're approaching this. 373 00:14:25,674 --> 00:14:28,394 Yeah. I really appreciate the clear examples too, 374 00:14:28,394 --> 00:14:30,794 Solomon. These are great. And as you were 375 00:14:30,794 --> 00:14:31,294 explaining 376 00:14:31,730 --> 00:14:33,730 all of these advancements and and what's on 377 00:14:33,730 --> 00:14:35,809 the horizon here, just the sheer number of 378 00:14:35,809 --> 00:14:38,550 patients at the population level this could impact 379 00:14:38,690 --> 00:14:41,029 is it sounds remarkable. And 380 00:14:41,410 --> 00:14:42,930 I also to your first point or your 381 00:14:42,930 --> 00:14:46,850 first example mentioning how these innovations could help 382 00:14:46,850 --> 00:14:47,350 with, 383 00:14:48,414 --> 00:14:49,534 I can't think of another word for it, 384 00:14:49,534 --> 00:14:52,095 but kind of prudent use of resources in 385 00:14:52,095 --> 00:14:54,495 the health care environment, which is so important 386 00:14:54,495 --> 00:14:56,815 from a cost perspective. It's just interesting to 387 00:14:56,815 --> 00:14:58,514 see how this affects everything from 388 00:14:58,894 --> 00:15:02,059 cost to the patient journey to health outcomes 389 00:15:02,059 --> 00:15:04,940 and, you know, that upstream approach to preventing 390 00:15:04,940 --> 00:15:06,080 conditions like cancer. 391 00:15:07,100 --> 00:15:09,419 So, again, I so appreciate the examples. I 392 00:15:09,419 --> 00:15:10,559 think that's really helpful, 393 00:15:10,940 --> 00:15:12,399 for myself and for listeners. 394 00:15:13,019 --> 00:15:14,725 But before I let you go today, you 395 00:15:14,725 --> 00:15:16,245 know, is there anything else that you wanted 396 00:15:16,245 --> 00:15:18,085 to share that maybe we haven't touched on 397 00:15:18,085 --> 00:15:20,644 yet, whether it's a final takeaway or maybe 398 00:15:20,644 --> 00:15:22,904 anything exciting on the horizon for Natera? 399 00:15:23,684 --> 00:15:26,825 Yeah. Ultimately, Natera is a highly patient centered 400 00:15:27,125 --> 00:15:27,625 organization. 401 00:15:28,165 --> 00:15:28,904 We employ 402 00:15:29,580 --> 00:15:30,559 over 6,000 403 00:15:31,340 --> 00:15:33,840 amazing, talented scientists, engineers, 404 00:15:34,620 --> 00:15:35,759 and more. And 405 00:15:36,379 --> 00:15:38,879 the number of people at our company 406 00:15:39,420 --> 00:15:42,334 who have either directly benefited from our technologies 407 00:15:42,634 --> 00:15:45,355 or have family members who have benefited is 408 00:15:45,355 --> 00:15:48,154 extraordinary. And you can visit our website and 409 00:15:48,154 --> 00:15:48,654 see 410 00:15:49,034 --> 00:15:51,934 so many patient testimonials and physician testimonials 411 00:15:52,475 --> 00:15:55,054 about how our technologies have impacted care, 412 00:15:55,559 --> 00:15:57,340 and improved patients' lives. 413 00:15:57,720 --> 00:15:59,879 So I'm I'm really proud of that, and 414 00:15:59,879 --> 00:16:02,139 I I'm very, very optimistic 415 00:16:02,679 --> 00:16:05,879 about the next phase for Natera and for 416 00:16:05,879 --> 00:16:07,419 the precision medicine industry. 417 00:16:07,879 --> 00:16:09,980 Really, like you said, you know, optimizing 418 00:16:10,955 --> 00:16:12,014 the use of resources, 419 00:16:12,475 --> 00:16:14,955 getting treatment to patients who need it, and 420 00:16:14,955 --> 00:16:17,274 the right treatment at the right time, which 421 00:16:17,274 --> 00:16:18,735 takes precision diagnostics, 422 00:16:19,195 --> 00:16:22,634 and also helping patients avoid unnecessary treatment or 423 00:16:22,634 --> 00:16:23,934 unnecessary interventions 424 00:16:24,470 --> 00:16:26,309 when it's not necessary. That's something that we 425 00:16:26,309 --> 00:16:29,769 accomplished in prenatal testing, where our Panorama 426 00:16:30,309 --> 00:16:32,009 noninvasive prenatal test 427 00:16:32,389 --> 00:16:35,690 now has probably resulted in an over eighty 428 00:16:35,750 --> 00:16:37,769 percent reduction in in amniocentesis 429 00:16:38,735 --> 00:16:41,695 and chorionic biopsy procedures across the country. It's 430 00:16:41,695 --> 00:16:42,514 just amazing. 431 00:16:42,975 --> 00:16:44,815 And so, you know, I'm I'm proud of 432 00:16:44,815 --> 00:16:46,975 what we do, and we've got a really 433 00:16:46,975 --> 00:16:49,955 bright future. So looking forward to, to continuing 434 00:16:50,014 --> 00:16:50,675 this conversation. 435 00:16:51,670 --> 00:16:54,550 Oh, likewise, Salomon. We're excited to keep tabs 436 00:16:54,550 --> 00:16:57,129 on Natera and all of the developments ahead. 437 00:16:57,350 --> 00:16:59,429 And your passion comes through throughout this whole 438 00:16:59,429 --> 00:17:01,269 conversation about the work that you do and 439 00:17:01,269 --> 00:17:02,950 that your team is doing. So I just 440 00:17:02,950 --> 00:17:05,234 wanna thank you for making the time for 441 00:17:05,234 --> 00:17:07,494 Becker's today and sharing your insights with us. 442 00:17:07,955 --> 00:17:09,955 Thank you so much. We'd also like to 443 00:17:09,955 --> 00:17:13,095 thank our podcast sponsor for today's episode, Natera. 444 00:17:13,837 --> 00:17:15,917 Listeners, be sure to tune into more podcasts 445 00:17:15,917 --> 00:17:18,717 from Becker's by visiting our podcast page at 446 00:17:18,717 --> 00:17:20,977 beckershospitalreview.com.